The Immunotherapy Series, Part One: A Brief History

[audio mp3="https://pdcn.co/e/rss.art19.com/episodes/353736d3-579a-405d-8a07-4548e5b0cd5c.mp3?rss_browser=BAhJIgljdXJsBjoGRVQ%3D--435795d5c850773aaa4739d968bd77a1dfd6f301"][/audio] The Immunotherapy Series, Part One: A Brief History

A Brief History of Immunotherapy. CAR-T, t-cell augmentation, and immunotherapy in general over the past decade. We will talk about why is this approach so compelling, and what its limitations have been to date.


Special guests:


Meghan Gutierrez

Chief Executive Officer

Lymphoma Research Foundation


Leo David Wang, M.D., Ph.D.

Assistant Professor, Department of Immuno-Oncology

Assistant Professor, Department of Pediatrics

City Of Hope


This series is brought to you ad-free by Adaptive Biotechnologies

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Kenny Kane

Kenny Kane is an entrepreneur, writer, and nonprofit innovator with 15+ years of experience leading organizations at the intersection of business, technology, and social impact. He is the CEO of Firmspace, CEO of the Testicular Cancer Foundation, and CTO/co-founder of Gryt Health.

A co-founder of Stupid Cancer, Kenny has built national awareness campaigns and scaled teams across nonprofits, health tech, and real estate. As an author, he writes about leadership, resilience, and building mission-driven organizations.

Previous
Previous

The Immunotherapy Series, Part Two: Beyond Immunotherapy

Next
Next

Out of Patients: Jen Horonjeff on Giving Patients Ownership in What They Help Create